President and Chief Commercial Officer of Endonovo’s Medical Division,
The
Weisberg Leads Negotiations.
In making the announcement, Weisberg commented: “We are actively negotiating with a veteran-owned company that will provide for the introduction of SofPulse® into the
Weisberg continued: “Endonovo is expanding our mission to become a prime supplier into the federal supply system and extending the benefits of SofPulse®. We are presently engaged in talks with a world-class government and academic collaboration to bring sensible pain management methods to the military.”
“NewCo” Spin-Off to Focus on SofPulse®
Endonovo is presently expanding sales and marketing efforts in support of its “Go to Market” strategy with the belief that new management and sales efforts can take the previously announced spin-off, NewCo, focused on SofPulse® medical devices and IP to generate more than
According to Weisberg: “Increasing sales with established government contractors is an efficient way to continue the commercialization of SofPulse®. We believe that by adding large government contracts to our sales and distribution channels through our military and government patient populations we will be able to reach the
VA.gov reports: “The Veterans Health Administration (VHA) is the largest integrated health care system in
Americanaddictioncenters.org reports: “The national opioid crisis affect every demographic but none so heavily as veterans. According to
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262363/pdf/IANN_54_2092896.pdf
PAIN MANAGEMENT PROGRAM INTRODUCED
Weisberg continued: "As an important element of our ‘Go to Market’ strategy, Endonovo has developed a ‘Pain Improvement Program’ (PIP) to focus on military and veterans’ surgical outcomes. We believe the PIP initiative will pave the way to improve the surgical outcomes and reduce opioid use for our active military heroes, their families as well as our veterans. Our Company is committed to improving the quality of life of our sons and daughters in active military service as well as those who have already served. Bringing SofPulse® non- opioid pain reduction benefits to our military, retired military veterans and other federal workers is a duty we do not take lightly.”
SofPulse® is a medical device that is designed to provide a viable alternative to opioid pain management for surgical patients. The device uses Pulsed Electro-Magnetic Field (PEMF) therapy to reduce pain and edema (swelling) following surgery. PEMF therapy is a non-invasive treatment that uses low-frequency electromagnetic fields to stimulate the body's natural healing processes and has shown to be a safe and effective alternative to opioids for managing pain and reducing edema following surgery.
Weisberg concluded: “I am extremely proud of our Company in its rapid completion of the PIP initiative to bring a proven drug-free pain management device to our military, government and veterans patient populations. Extending the benefits of SofPulse® into patient populations that are severely impacted by the opioid crisis was viewed by our Company as a mission critical requirement for the re-launch of SofPulse® as a holistic drug-free alternative to opioids for surgical pain management.”
About Endonovo Therapeutics, Inc.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate", "believe", "plan", "estimate", "expect", "intend" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the
Investor Relations Contact:
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com
Media Contact:
(310) 804-7037
greg@gregmcandrews.com
![](https://ml.globenewswire.com/media/ZTNhYmVhOTQtODk0Zi00OTQ1LTk2Y2QtZWUyMzU4MzBmYjllLTUwMDA0OTI3NA==/tiny/Endonovo-Therapeutics-Inc-.png)
2023 GlobeNewswire, Inc., source